Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
Top Cited Papers
- 1 October 2008
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 372 (9647), 1385-1393
- https://doi.org/10.1016/s0140-6736(08)61411-7
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 2007
- Candesartan- and Atenolol-Based Treatments Induce Different Patterns of Carotid Artery and Left Ventricular Remodeling in HypertensionStroke, 2006
- Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen)Diabetes & Metabolism, 2005
- The Renin-Angiotensin System and the Developing Retinal VasculatureInvestigative Opthalmology & Visual Science, 2005
- The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristicsJournal of the Renin-Angiotensin-Aldosterone System, 2005
- The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study designJournal of the Renin-Angiotensin-Aldosterone System, 2002
- Comparative Effects of Ramipril on Ambulatory and Office Blood PressuresHypertension, 2001
- UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosisDiabetologia, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- A Hybrid Algorithm for Computation of the Nonparametric Maximum Likelihood Estimator from Censored DataJournal of the American Statistical Association, 1997